Download now: Gold and Silver Mining Stocks

Organ Growth Company to IPO

Biotech Develops "Bioreactors"

Written by Swagato Chakravorty
Posted December 13, 2012

Harvard Apparatus Regenerative Technology Inc., a subsidiary of Harvard Bioscience Inc. (NASDAQ: HBIO), intends to seek around $20 million in its IPO.

The company is working on creating “bioreactor” units that can be used to grow organs outside of the body. Obviously, that has enormous implications for patients who are on donor wait-lists.

Harvard Bioscience will own 80 percent of the shares following its IPO, with plans of eventually handing over the entire business to its stockholders.

From the Boston Herald:

“We believe our technology could enable surgeons to cure nearly all primary trachea cancers,” the company said in the filing. “Our products address the critical challenges to trachea transplant: the shortage of suitable donor tracheas and the risk and expense of lifelong anti-rejection drug therapy.”

Harvard Apparatus was incorporated in May of this year. The company has already tested what it calls a “synthetic scaffold,” which can develop a replacement trachea.

The IPO mentions that this technology has seen success in six surgeries involving human airway transplants. FDA approval for trachea transplant products is expected by 2017, which would allow the company to enter a market estimated to be worth in excess of $300 million per year.

The company, which filed on December 11, will list under the symbol “HART”.


The Best Free Investment You'll Ever Make

Sign up for the free Wealth Daily e-letter below.

In each issue, you'll get our best investment research, designed to help you build a lifetime of wealth, minus the risk.


By signing up, you'll instantly receive our new report: Surviving the Coming Economic Collapse.... Finding The Most Profitable Investing Opportunities For Your Portfolio.
We Protect Your Privacy

Related Articles

New Jersey Biotech Companies
New Jersey has reported a profitable two years in the biotech sector despite economic shortcomings.
2012 Biotech Boom
This year has been great for the biotech industry, but it may have been pushed by a slump in pharmaceutical companies.
Biotech Company Raises $210 Million
Private biotech firm Intarcia Therapeutics has a unique, once-yearly type 2 diabetes therapy...


What is the benefit of the email subscription?
While the Wealth Daily website offers access to the articles and reports, as a newsletter subscriber you will be among the first to receive access to the valuable advice, delivered directly to your inbox daily, and you will have access to deals on our exclusive services.
Greece's Keynesian Experiment
Big Government Doesn't Work
China's World Domination
And Why it's Not Going to Happen
Should Greece Pay Its Debt?
The Case for a Greek Default
Gold's Early Warning
Deflation May Be Coming
How to Retire Like a King
5 Tips for a $1 Million Retirement
Guaranteed Returns in Cotton Futures!
Uncle Sam's $5 Billion Cotton Scam
Investing in Rhenium
More Valuable Than Oil and Gold Combined!
How to Retire Like a King
5 Tips for a $1 Million Retirement
Greece is Screwed!
10 Ways to Protect Yourself from the Global Economic Crisis
Investing in the Next Silver Bull Market
Silver Short Selling: Manipulation or Opportunity?